Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2016-10-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/rccm.201604-0700OCPMID 27748623PMCID PMC5363966
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Variable-Number Tandem-Repeat Analysis of Respiratory and Household Water Biofilm Isolates of “Mycobacterium avium subsp. hominissuis” with Establishment of a PCR Database

  2016cited by this paper
• WS02.3 Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung disease (LD)

  2015cited by this paper
• Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease.

  2015cited by this paper
• Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)

  2015cited by this paper
• Case Report of a Patient With Treatment-Refractory Nontuberculous Mycobacteria (NTM) Lung Infection Treated With Once Daily (QD) Liposomal Amikacin for Inhalation (LAI)

  2015cited by this paper
• Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.

  2014cited by this paper
• Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection

  2014cited by this paper
• Nontuberculous Mycobacterial Disease Mortality in the United States, 1999–2010: A Population-Based Comparative Study

  2014cited by this paper
• Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

  2013cited by this paper
• In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates

  2013cited by this paper
• Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010

  2013cited by this paper
• Mycobacterial Interspersed Repetitive-Unit–Variable-Number Tandem-Repeat (MIRU-VNTR) Genotyping of Mycobacterium intracellulare for Strain Comparison with Establishment of a PCR-Based Database

  2012cited by this paper
• Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease.

  2012cited by this paper
• Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.

  2012cited by this paper
• Therapy of refractory nontuberculous mycobacterial lung disease

  2012cited by this paper
• Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease.

  2011cited by this paper
• Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease.

  2010cited by this paper
• Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection

  2009cited by this paper
• When and how to treat pulmonary non‐tuberculous mycobacterial diseases

  2009cited by this paper
• Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands

  2009cited by this paper
• Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.

  2008cited by this paper
• An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

  2007cited by this paper
• Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases.

  2004cited by this paper
• Evaluation of the MicroSeq System for Identification of Mycobacteria by 16S Ribosomal DNA Sequencing and Its Integration into a Routine Clinical Mycobacteriology Laboratory

  2003cited by this paper
• ATS statement: guidelines for the six-minute walk test.

  2002cited by this paper
• Rapid identification of mycobacteria to species level by PCR-restriction fragment length polymorphism analysis of the hsp65 gene and proposition of an algorithm to differentiate 34 mycobacterial species

  1997cited by this paper
• Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients.

  1996cited by this paper
• Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease.

  1994cited by this paper
• Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity

  1989cited by this paper

• Nanoparticle-based inhalation therapy for targeted treatment of multidrug-resistant pulmonary tuberculosis: A review

  2026cites this paper
• From anonymity to stardom: history of nontuberculous mycobacterial disease in humans

  2026cites this paper
• Recent approaches of proliposome-based dry powder inhalation for pulmonary delivery

  2026cites this paper
• Recent advances in immunopathogenesis and clinical practice: mastering the challenge-managing of non-tuberculous mycobacteria

  2025cites this paper
• Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.

  2025cites this paper
• The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment

  2025cites this paper
• Core outcome domains for Mycobacterium avium complex pulmonary disease: a MACCOR study

  2025cites this paper
• Advances in Targeted Engineered Nanoparticle-Based Therapeutics for Respiratory Diseases: Current Insights and Future Perspectives

  2025cites this paper
• Current advancements in nanoparticles for vaccines and drug delivery for the treatment of tuberculosis.

  2025cites this paper
• Analytical Methodologies for Anti-Infective Orphan Drugs: A Comprehensive Review of FDA Approvals (2013-2023) Part 1.

  2025cites this paper
• Laboratory diagnosis of nontuberculous Mycobacteria – an update – Part 2: Specimen collection and laboratory work-up

  2025cites this paper
• Implications of Intravenous and Inhaled Amikacin Breakpoint Reporting for Mycobacterium avium Complex Pulmonary Isolates

  2025cites this paper
• Mycobacterium abscessus group pulmonary disease

  2025cites this paper
• A Pilot Study to Assess the Effect of Intermittent Inhaled Nitric Oxide as Treatment of Nontuberculous Mycobacteria Lung Infection.

  2025cites this paper
• Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections

  2025cites this paper
• Liposome-Based Nanoparticle Delivery Systems for Lung Diseases: Opportunities and Challenges

  2025cites this paper
• Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges

  2025influential citation
• Age- and Gender-Specific Distribution and Susceptibility-Guided Multidrug Strategies in NTM Lung Disease: A retrospective study from a specialized hospital in China

  2025cites this paper
• Aminoglycoside susceptibility and treatment outcomes in Mycobacterium avium complex pulmonary disease.

  2025cites this paper
• Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies

  2025cites this paper
• Lipid-based nanomedicines for the treatment of bacterial respiratory infections: current state and new perspectives.

  2024cites this paper
• Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation Suspension

  2024cites this paper
• Interplay of nano-based delivery systems and protein signalling in ameliorating lung diseases

  2024cites this paper
• Treatment for non-tuberculous mycobacteria: challenges and prospects

  2024influential citation
• Nontuberculous Mycobacteria Pulmonary Infection in Children with Cystic Fibrosis

  2024cites this paper
• Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease

  2024cites this paper
• Amikacin Liposomal Inhalation Suspension for Non-Tuberculous Mycobacteria Lung Infection: A Greek Observational Study

  2024influential citation
• Epidemiological Characteristics of Nontuberculous Mycobacterial Pulmonary Disease in South Korea: A Meta-analysis of Individual Participant Data

  2024cites this paper
• Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease

  2023cites this paper
• Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?

  2023cites this paper
• Preparation of protein-loaded nanoparticles based on poly(succinimide)-oleylamine for sustained protein release: a two-step nanoprecipitation method

  2023cites this paper
• Aerosol Pulmonary Immune Engineering.

  2023cites this paper
• An evolving perspective on novel modified release drug delivery systems for inhalational therapy

  2023cites this paper
• Microbiological Cure at Treatment Completion Is Associated With Longer Survival in Patients With Mycobacterium avium Complex Pulmonary Disease.

  2023cites this paper
• Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.

  2023cites this paper
• Mycobacterium xenopi related spine infections: A case report and systematic literature review

  2023cites this paper
• Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator Modulators

  2023cites this paper
• [A pharmacologic approach to treatment of Mycobacterium abscessus pulmonary disease].

  2023cites this paper
• Treatment Approaches to Mycobacterium abscessus Pulmonary Disease.

  2023cites this paper
• On the Path to Predicting Immune Responses in the Lung: Modeling the Pulmonary Innate Immune system at the Air-Liquid Interface (ALI).

  2023cites this paper
• Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease

  2022cites this paper
• Amikacin Liposome Inhalation Suspension Clinical Benefit-Risk Assessment for Refractory MAC Lung Disease

  2022influential citation
• Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations

  2022cites this paper
• Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery

  2022cites this paper
• Liposomal amikacin and Mycobacterium abscessus: intimate interactions inside eukaryotic cells.

  2022cites this paper
• Amikacin liposome and Mycobacterium avium complex: A systematic review

  2022cites this paper
• Mutation patterns of resistance genes for macrolides, aminoglycosides, and rifampicin in non-tuberculous mycobacteria isolates from Kenya

  2022cites this paper
• Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3.

  2022cites this paper
• Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection

  2022cites this paper
• Nontuberculous Mycobacteria: Diagnosis and Therapy.

  2022cites this paper
• A Review on Mycobacteriophages: From Classification to Applications

  2022cites this paper
• Antimicrobial Strategies for Cystic Fibrosis

  2022cites this paper
• Indian Guidelines on Nebulization Therapy.

  2022cites this paper
• Multiresistant organisms: bacteria and beyond

  2022cites this paper
• Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease

  2022cites this paper
• Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?

  2022cites this paper
• Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach

  2022cites this paper
• ERS International Congress 2021: highlights from the Respiratory Infections Assembly

  2022cites this paper
• Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience

  2022cites this paper
• Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease.

  2022cites this paper
• Nanodeliovery based Chinese medicine's bioactive compounds for treatment of respiratory disorders

  2022cites this paper
• Diagnosis and Management of Pulmonary NTM with a Focus on Mycobacterium avium Complex and Mycobacterium abscessus: Challenges and Prospects

  2022cites this paper
• A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study

  2022cites this paper
• In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates

  2022cites this paper
• Studies of the Specific Activity of Aerosolized Isoniazid against Tuberculosis in a Mouse Model

  2022cites this paper
• Current Molecular Therapeutic Agents and Drug Candidates for Mycobacterium abscessus

  2021cites this paper
• Review of the international clinical practice guidelines for the treatment of lung infections caused by nontuberculous mycobacteria

  2021cites this paper
• Bioengineering approach for pulmonary drug delivery

  2021cites this paper
• Pharmacotherapy for nontuberculous mycobacterial pulmonary disease.

  2021cites this paper
• Nontuberculous Mycobacteria

  2021cites this paper
• Inhalable liposomes for treating lung diseases: clinical development and challenges

  2021cites this paper
• Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

  2021cites this paper
• HYPERAMMONEMIC SYNDROME AND UREAPLASMA IN LUNG TRANSPLANT RECIPIENTS and a prospective INHALED (NON-LIPSOSOMAL) AMIKACIN IN THE TREATMENT OF PULMONARY INFECTIONS DUE TO MYCOBACTERIUM ABSCESSUS

  2021cites this paper
• The role of amikacin in the treatment of nontuberculous mycobacterial disease

  2021cites this paper
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis

  2021cites this paper
• Efficacy estimation of a combination of triple antimicrobial agents against clinical isolates of Mycobacterium abscessus subsp. abscessus in vitro

  2021cites this paper
• Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease

  2021cites this paper
• Radiographic severity and treatment outcome of Mycobacterium abscessus complex pulmonary disease.

  2021cites this paper
• Nanobiosystems for Antimicrobial Drug-Resistant Infections

  2021cites this paper
• Laryngeal Injury Due to Amikacin Inhalation for Refractory Mycobacterium avium Complex Infection.

  2021cites this paper
• Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection

  2021influential citation
• Development of Drugs for Nontuberculous Mycobacterial Disease

  2021influential citation
• Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use

  2021cites this paper
• Application of nanotechnology in drug delivery systems for respiratory diseases

  2021cites this paper
• An Overview of the Biology of a Long-Acting Inhaled Treprostinil Prodrug.

  2021cites this paper
• Outcomes of inhaled amikacin-containing multidrug regimens for Mycobacterium abscessus pulmonary disease.

  2021cites this paper
• Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways

  2021cites this paper
• Liposomes: An emerging approach for treatment of cancer.

  2021cites this paper
• Resistant tuberculosis: the latest advancements of second-line antibiotic inhalation products.

  2021cites this paper
• Considerations for Phage Therapy Against Mycobacterium abscessus

  2021cites this paper
• Rapid macrolide and amikacin resistance testing for Mycobacterium abscessus in people with cystic fibrosis.

  2021cites this paper
• Nontuberculous mycobacteria in cystic fibrosis

  2021cites this paper
• Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

  2021cites this paper
• Nanoparticle Delivery Systems with Cell-specific Targeting for Pulmonary Diseases.

  2020cites this paper
• How I Do It: Managing M. avium complex lung disease with a little help from my friend.

  2020cites this paper
• Nuevos antibióticos inhalados y formas de administración

  2020cites this paper
• Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.

  2020influential citation
• Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US FDA Workshop.

  2020cites this paper
• Liposomes in the treatment of chronic respiratory conditions

  2020cites this paper
• Multirobot Collaborative Navigation Algorithms Based on Odometer/Vision Information Fusion

  2020cites this paper